Induced Pluripotent Stem Cell Derived Human Lung Organoids to Map and Treat the SARS-CoV2 Infections In Vitro – DocWire News

This article was originally published here

Adv Exp Med Biol. 2021 Jan 1. doi: 10.1007/5584_2020_613. Online ahead of print.

ABSTRACT

COVID-19 is the current day pandemic that has claimed around 1,054,604 lives globally till date. Moreover, the number of deaths is going to increase over the next few months until the pandemic comes to an end, and a second wave has also been reported in few countries. Most interestingly, the death rate among certain populations from the same COVID-19 infection is highly variable. For instance, the European populations show a very high death rate, in contrast to the populations from Chinese ethnicities. Amongst all the closed cases with an outcome (total recovered + total died), the death rate in Italy is 13%, Iran is 6%, China is 5%, Brazil is 3%, The United States of America is 2%, India 2%, Israel is 1% as of October 08, 2020. However, the percentage was higher during the early phase of the pandemic. Moreover, the global death rate amongst all the patients with an outcome is 4%. Here we have reviewed virus-transmitted various respiratory tract infections and postulated a better understanding of SARS-CoV2 using lung stem cell organoids in vitro. Hence, here we propose the strategies of understanding first the infectivity/severity ratio of COVID-19 infections using various ethnicity originated induced pluripotent stem cell-derived lung stem cell organoids in vitro. The greater the infectivity to severity ratio, the better the disease outcome with the value of 1 being the worst disease outcome. This strategy will be useful for understanding the infectivity/severity ratio of virus induced respiratory tract infections for a possible betterment of community-based disease management. Also, such a strategy will be useful for screening the effect of various antiviral drugs/repurposed drugs for their efficacy in vitro.

PMID:33385178 | DOI:10.1007/5584_2020_613

Read the original post:
Induced Pluripotent Stem Cell Derived Human Lung Organoids to Map and Treat the SARS-CoV2 Infections In Vitro - DocWire News

Creative Medical Technology Holdings Announces Patent filing based on Preclinical Data in Model of Heart Attack using ImmCelz Regenerative…

PHOENIX, Dec. 31, 2020 /PRNewswire/ --(OTC CELZ) Creative Medical Technology Holdings Inc. announced today positive preclinical data using ImmCelz in treatment of a model of heart attack.

Patent application #63/132472, entitled "Treatment of Heart Failure and/or Post Infarct Pathological Remodeling by Ex Vivo Reprogrammed Immune Cells" covers data in which mice with restricted blood flow to the heart had significantly improved survival when treated with ImmCelz as compared to control mice.

"The role of the immune system in numerous aspects of regenerative medicine can not be overstated." Said Dr. Amit Patel, Board Member of the Company and co-inventor of the patent. "The data described today, while preliminary, supports the belief that ImmCelz, which is a "regenerative immunotherapy" can be applied across a broad range of conditions."

The ImmCelz product, based on decades of immunological research by Drs Thomas Ichim and Amit Patel, involves extraction of patient immune cells, "training" the immune cells to exhibit regenerative properties by incubation with regenerative cells outside of the body, followed by re-infusion of the patient's own cells. To date the Company has demonstrated that ImmCelz has therapeutic activity in stroke and liver failure.

"It is my honor that the work we initiated more than a decade ago is coming to fruition." Said Thomas Ichim, Ph.D, coinventor of the patent. "Ten years ago, Dr. Patel, myself and a team of colleagues described the potent synergies that occur when various cell types are utilized in combination for treatment of heart failure1. ImmCelz is the product of all these years of working and perfecting multi-cellular approaches to regenerative medicine."

"As we round out 2020, we have significantly expanded our Intellectual Property portfolio based on many years of collaborative research and development. Utilizing the ImmCelz technology for the treatment of heart failure is an excellent addition to this robust patent portfolio as it effects millions of patients in the U.S. alone. Patients with end stage heart failure in many cases have no options but heart transplantation, which is extremely limited." Said Timothy Warbington, President and CEO of the Company. "We are excited with the progress that the Company is making in advancing ImmCelz, which approaches regenerative medicine from a completely unique perspective. Given that the active cells in ImmCelz are derived from the same patient, we anticipate an accelerated path to FDA Investigational New Drug (IND) clearance."

"We encourage industry colleagues and other interested parties to review our early priority date patent filings to learn more about the ImmCelz technology and how it applies to multiple indications" Mr. Warbington further said.

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in stem cell technology in the fields of urology, neurology and orthopedics and trades on the OTC under the ticker symbol CELZ. For further information about the company, please visitwww.creativemedicaltechnology.com.

Forward Looking Statements

OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website atwww.sec.gov.

Creativemedicaltechnology.com http://www.StemSpine.com http://www.Caverstem.com http://www.Femcelz.com

1 Ichim et al. Combination stem cell therapy for heart failure. Int Arch Med. 2010; 3: 5. Combination stem cell therapy for heart failure (nih.gov)

SOURCE Creative Medical Technology Holdings, Inc.

Home

Go here to see the original:
Creative Medical Technology Holdings Announces Patent filing based on Preclinical Data in Model of Heart Attack using ImmCelz Regenerative...

Haywards Heath carer trying to raise funds for MS treatment – The Argus

A FORMER NHS care assistant is hoping the new year will see her raise 40,000 to fund groundbreaking treatment.

Joceline Colvert, 41, from Haywards Heath was diagnosed with multiple sclerosis (MS) at the age of 22.

During the last few years her condition has deteriorated and forced her to give up her job as a nursing assistant.

Haematopoietic stem cell transplantation, or HSCT, is available on the NHS but because Jocelines diagnosis was more than 15 years ago, she does not qualify for NHS treatment.

It means she has to fund treatment outside the UK.

READ MORE:'My MS relapse left me unable to walk or smile' - chef reveals devastating impact

She has raised 27,000 for the procedure at a specialist clinic in Russia, due to start in March next year.

The treatment involves removing the patients stem cells, followed by chemotherapy and then re-introducing the cleansed stem cells, effectively erasing the bodys memory of MS.

Joceline said: I am so excited about the difference the treatment could make to my life.

I bought my first wheelchair this year and decided I had to do everything to stop my mobility deteriorating any further.

I was devastated I didnt qualify for treatment on the NHS but rather than become despondent Ive put my energy into funding the treatment independently.

People have been so generous and I cant thank family, friends and complete strangers enough for their help so far.

Im hoping that I can reach the fundraising target so I can make the trip to Moscow.

Joceline Colvert hopes to halt the progress of her MS

The treatment has an 80 to 90 per cent success rate.

HSCT is not expected to cure MS, however in most cases it freezes it and stops it getting any worse and most patients see their mobility improve.

Joceline said: For years I have been dreading the future but for the first time I am excited about it and hopeful that I will be able to walk unaided again.

My dream is to be able to take my ageing dog for a proper walk in the future.

READ MORE:Mother refuses to be 'beaten' by MS after losing her son and husband

Although my husband takes her out, one of the hardest things is not being able to enjoy time outside with her.

The donations to Jocelines Gofundme page have reached two thirds of 40,000 needed to fund the treatment.

If you would like to donate and help Joceline make it to Russia, visit Jocelines GoFundMe page https://gf.me/u/y538k2

Original post:
Haywards Heath carer trying to raise funds for MS treatment - The Argus

Chronic graft-versus-host disease in children and adolescents with thalassemia after hematopoietic stem cell transplantation – DocWire News

This article was originally published here

Int J Hematol. 2021 Jan 1. doi: 10.1007/s12185-020-03055-w. Online ahead of print.

ABSTRACT

Data on chronic graft-versus-host disease (cGVHD) in patients with thalassemia after hematopoietic stem cell transplantation (HSCT) have not been specifically explored. The present study aimed to determine the incidence and clinical manifestations of cGVHD in children and adolescents with thalassemia who underwent HSCT and to compare healthcare utilization and medical cost between patients with and without cGVHD. We retrospectively analyzed the presentations, treatments, and outcomes of historical cGVHD (Seattle criteria), post-transplant admissions and direct medical cost for HSCT patients (n = 66). We used the 2014 NIH consensus criteria to reclassify the diagnosis of cGVHD (NIH cGVHD). Among 28 historical cGVHD patients, 13 (46.4%) fulfilled the NIH criteria. Reasons why the NIH criteria were unmet were reclassification as late acute GVHD and presence of distinctive signs without confirmatory tests. At 2 years after HSCT, the cumulative incidence of NIH cGVHD was 21.67% (95% CI, 12.31-32.74%). Lung cGVHD was associated with inferior survival with a hazard ratio of 13.6 (95% CI, 1.42-131.48). Patients with historical cGVHD had significantly increased frequency of inpatient admissions and medical cost. In conclusion, cGVHD was common in children with thalassemia receiving HSCT. Patients with cGVHD required prolonged immunosuppressive treatment and incurred high medical expenses.

PMID:33385291 | DOI:10.1007/s12185-020-03055-w

Originally posted here:
Chronic graft-versus-host disease in children and adolescents with thalassemia after hematopoietic stem cell transplantation - DocWire News

COVID-19-positive cancer patients undergoing active anticancer treatment: An analysis of clinical features and outcomes – DocWire News

This article was originally published here

Hematol Oncol Stem Cell Ther. 2020 Dec 24:S1658-3876(20)30180-1. doi: 10.1016/j.hemonc.2020.12.001. Online ahead of print.

ABSTRACT

BACKGROUND: Cancer patients, particularly those on active anticancer treatment, are reportedly at a high risk of severe coronavirus disease 2019 (COVID-19) infection and death. This study aimed to describe the clinical characteristics and outcomes of patients diagnosed with COVID-19 whilst on anticancer treatment in a developing country.

METHODS: This is a retrospective observational study of all adult cancer patients at Shaukat Khanum Memorial Cancer Hospital and Research Centre, Pakistan, from March 15, 2020 to July 10, 2020, diagnosed with COVID-19 within 4 weeks of receiving anticancer treatment, where a purposive sampling was performed. Cancer patients who did not receive anticancer treatment and clinical or radiological diagnosis of COVID-19 without a positive reverse transcription-polymerase chain reaction (RT-PCR) test were excluded. The primary endpoint was all-cause mortality after 30 days of COVID-19 test. Data was analyzed with SPSS version 23 (SPSS Inc., Chicago, IL, USA). Categorical parameters were computed using chi-square test, keeping p value < 0.05 as significant.

RESULTS: A total of 201 cancer patients with COVID-19 were analyzed. The median age of patients was 45 (18-78) years. Mild symptoms were present in 162 (80.6%) patients, whereas severe symptoms were present in 39 (19.4%) patients. The risk of death was statistically significant (p < .05) amongst patients with age greater than 50 years, metastatic disease, and ongoing palliative anticancer treatment. Anticancer treatment (chemotherapy, radiotherapy, hormonal therapy, targeted therapy, and surgery) received within preceding 4 weeks had no statistically significant (p > .05) impact on mortality.

CONCLUSIONS: In cancer patients with COVID-19, mortality appears to be principally driven by age, advanced stage of the disease, and palliative intent of cancer treatment. We did not identify evidence that cancer patients on chemotherapy are at significant risk of mortality from COVID-19 correlating to those not on chemotherapy.

PMID:33387453 | DOI:10.1016/j.hemonc.2020.12.001

Read more:
COVID-19-positive cancer patients undergoing active anticancer treatment: An analysis of clinical features and outcomes - DocWire News

Cell Therapy Market 2020-2026 by Growth, Demand and Upcoming Business Opportunities – Farming Sector

The latest Cell Therapy Market report considers size, application segment, type, regional outlook, market demand, latest trends, as well as Cell Therapy Market share and revenue by manufacturers, the main company profiles, and forecasts of future growth potential. Analyses the current size of the market and its evolution in this sector over the coming years.

The report offers a critical hypothesis that identifies with the Cell Therapy Market by studying its breakdown. The global market with respect to Cell Therapy Market size, market share, growth factor, major supplier, revenue, product demand, sales size, quantity, cost structure, and new development in the Cell Therapy Market. The report also includes data on models and improvements, along with target industries and materials, limitations, and advancements. The formulation of this Cell Therapy Market research report has adopted the highest level of mind, practical solutions, dedicated research and analysis, innovation, integrated approaches, and advanced technology, among others. The insightful research report on the Cell Therapy Market includes Porters five forces analysis and SWOT analysis to understand the factors that influence the behavior of consumers and vendors.

Get | Download Sample Copy @ https://www.adroitmarketresearch.com/contacts/request-sample/611?utm_source=AD

Cell Therapy Market: Competitive Landscape

The competitive landscape of a market explains strategies incorporated by key players of the market. Key developments and shifts in management in recent years by players have been explained through company profiling. This helps readers to understand the trends that will accelerate the growth of the market. It also includes investment strategies, marketing strategies, and product development plans adopted by major players in the market. The market forecast will help readers make better investments.

Impact of Covid-19 in Cell Therapy Market: The utility-owned segment is mainly being driven by increasing financial incentives and regulatory supports from the governments globally. The current utility-owned Cell Therapy Market are affected primarily by the COVID-19 pandemic. Most of the projects in China, the US, Germany, and South Korea are delayed, and the companies are facing short-term operational issues due to supply chain constraints and lack of site access due to the COVID-19 outbreak. Asia-Pacific is anticipated to get highly affected by the spread of the COVID-19 due to the effect of the pandemic in China, Japan, and India.

Key Players Profiled in the Report on the Cell Therapy Market

JCR Pharmaceuticals Co., Ltd., Kolon TissueGene, Inc.; and Medipost and many more.

For more informative information, please visit us @ https://www.adroitmarketresearch.com/industry-reports/cell-therapy-market?utm_source=AD

Cell Therapy Market Regional Analysis Includes:

1. Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia) 2. Europe (Turkey, Germany, Russia UK, Italy, France, etc.) 3. North America (the United States, Mexico, and Canada.) 4. South America (Brazil etc.) 5. The Middle East and Africa (GCC Countries and Egypt.)

Cell Therapy Market: Segment Analysis

This section of the report includes segmentation such as application, product type, and end-user. These segmentations aid in determining parts of the market that will progress more than others. The segmentation analysis provides information about the key elements that are thriving the specific segments better than others. It helps readers to understand strategies to make sound investments. The global Cell Therapy market is segmented on the basis of product type, applications, and its end users.

Cell Therapy Market Segment by Type:

By Use & Type Outlook, (Clinical-use,By Cell Therapy Type,,Non-stem Cell Therapies,Stem Cell Therapies,BM, Blood, & Umbilical Cord-derived Stem Cells,Adipose derived cells,Others), By Therapeutic Area, (Malignancies,Muscoskeletal Disorders,Autoimmune Disorders,Dermatology,Others,Research-use), By Therapy Type, (Allogenic Therapies,Autologous Therapies)

Key Highlights of the Table of Contents:

1. Cell Therapy Market Study Coverage: It includes key market segments, key manufacturers covered, the scope of products offered in the years considered, Cell Therapy Market and study objectives. Additionally, it touches the segmentation study provided in the report on the basis of the type of product and applications.

2. Cell Therapy Market Executive summary: This section emphasizes the key studies, market growth rate, competitive landscape, market drivers, trends, and issues in addition to the macroscopic indicators.

3. Cell Therapy Market Production by Region: The report delivers data related to import and export, revenue, production, and key players of all regional markets studied are covered in this section.

4. Cell Therapy Market Profile of Manufacturers: Analysis of each market player profiled is detailed in this section. This segment also provides SWOT analysis, products, production, value, capacity, and other vital factors of the individual player.

Further Key Aspects Of The Report Indicate That:

Chapter 1: Market Definition and Segment by Type, End-Use & Major Regions Market Size Chapter 2: Global Production & Consumption Market by Type and End-Use Chapter 3: Europe Production & Consumption Market by Type and End-Use Chapter 4: America Production & Consumption Market by Type and End-Use Chapter 5: Asia Production & Consumption Market by Type and End-Use Chapter 6: Oceania Production & Consumption Market by Type and End-Use Chapter 7: Africa Production & Consumption Market by Type and End-Use Chapter 8: Global Market Forecast by Type, End-Use and Region Chapter 9: Company information, Sales, Cost, Margin, news etc. Chapter 10: Market Competition by Companies and Market Concentration Ratio Chapter 11: Market Impact by Coronavirus. Chapter 12: Industry Summary

If you have any custom requirements, please let us know and we will offer you the customized report as per your requirements.

Ask for Discount @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/611?utm_source=AD

About Us :

Contact Us :

Ryan Johnson Account Manager Global 3131 McKinney Ave Ste 600, Dallas, TX75204, U.S.A. Phone No.: USA: +1 972-362 -8199/ +91 9665341414

The rest is here:
Cell Therapy Market 2020-2026 by Growth, Demand and Upcoming Business Opportunities - Farming Sector

Rheumatoid Arthritis Stem Cell Therapy Market Latest Trends and Future Growth Study by 2029 – Farming Sector

Global Rheumatoid Arthritis Stem Cell Therapy Market: Overview

Rheumatoid arthritis is an inflammatory disease of the bodys supportive tissues, usually affecting an individuals toes and fingers. Inflammation is triggered by an abnormal response to the bodys normally functioning tissues. This results in malformed joints and severe pain. Stem cells are novel cells that are generated in regenerative centers of the body. They can be transformed into any other cell type in the body with the right kind of stimulus.

Get Exclusive PDF Sample Copy Of This Report:https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6864

Stem cell therapy for rheumatoid arthritis works on the principle of such cellular replacement. Stem cells are injected into a patients body and are transformed on site into anti inflammatory cells that limit the spread of this disease. Stem cells work better than traditional inflammation suppressing medicines because they are more organic and act in a targeted manner. In light of the development of innovations in allopathic medicine and demand of people for better healthcare facilities, the market for rheumatoid arthritis stem cell therapy is expected to grow at a commendable pace from 2019 to 2029, opines TMRR.

Global Rheumatoid Arthritis Stem Cell Therapy Market: Competitive Landscape

Handful of pharmaceutical manufacturing facilities is seen to be involved in the production of stem cell therapy solutions.

Significant players n the market include.

Some of these manufacturers are established players in the pharmaceutical industry and have branched into the foray of stem cell therapy. Their established base for pharmaceutical therapy makes the distribution and marketing of stem cell therapy easier. Innovations in this market scenario are funded by these players to increase patient compliance with therapy.

Buy This Report @https://www.tmrresearch.com/checkout?rep_id=6864<ype=S

Global Rheumatoid Arthritis Stem Cell Therapy Market: Key Trends and Drivers

Global Rheumatoid Arthritis Stem Cell Therapy Market: Regional Analysis

North America and Europe currently lead in the rheumatoid arthritis stem cell therapy market. This might be because of the presence of a robust healthcare infrastructure that is under pressure from people for better facilities. Moreover, most innovatory laboratories are based in these regions and enjoy supple funding from regional governments. Population in these regions too is more aged than in other regions of the world. Hence, market growth for stem cell therapy should be good here.

The Asia Pacific region (APAC) is expected to register the fastest growth in this market in the coming years. A growing healthcare infrastructure that derives protocol from western medicine should support the growth of stem cell therapy. Population here is also expected to age in future decades, and an increasingly stressful lifestyle shall undoubtedly bring an increase in incidence of stressful conditions like rheumatoid arthritis.

Based on treatment type, the global rheumatoid arthritis stem cell therapy market can be segmented into:

Based on application, the global rheumatoid arthritis stem cell therapy market can be segmented into:

Based on distribution channel, the global rheumatoid arthritis stem cell therapy market can be segmented into:

Based on geography, the global rheumatoid arthritis stem cell therapy market can be segmented into:

To know more about the table of contents, you can click @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=6864

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to busi-ness entities keen on succeeding in todays supercharged economic climate. Armed with an experi-enced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research, 3739 Balboa St # 1097, San Francisco, CA 94121 United States Tel: +1-415-520-1050

Continue reading here:
Rheumatoid Arthritis Stem Cell Therapy Market Latest Trends and Future Growth Study by 2029 - Farming Sector

Creative Medical Technology Holdings Announces Reversion of Liver Failure Using ImmCelz Personalized Cellular Immunotherapy in Preclinical Model -…

PHOENIX, Dec. 29, 2020 /PRNewswire/ --(OTC-CELZ)Creative Medical Technology Holdings Inc. announced today novel data and patent filing No. 63131261 describing the ability of ImmCelz to reverse liver failure in the carbon tetrachloride preclinical model of hepatocyte necrosis.

These findings are the basis for a patent filing covering various means of generating the ImmCelz product in a hepatoprotective specific manner. The Company has previously reported that ImmCelz is capable of treating animal models of stroke,1 as well as inducing "immunological tolerance" in a model of autoimmune rheumatoid arthritis.2

The work is an extension of previously published findings of Dr. Thomas E. Ichim, in which mesenchymal stem cells were capable of inhibiting progression of liver failure.3

"I am proud of the work the team at Creative Medical Technologies is conducting in advancing the concept of immunologically-mediated regeneration,"said Dr. Ichim, Co-inventor of the patent. "ImmCelz is an advancement on our previous liver failure work due to the fact that we have shown transfer of regenerative activity from the stem cell to the immune cell. Immune cells possess ability to home to injured tissues faster than stem cells due to their smaller size. Additionally, immune cells possess immunological memory, which we believe may be applied to the concept of regeneration."

"While stem cell therapeutics are recognized as the future of medicine, I believe it is important to realize that many activities of stem cells are mediated by changes to the immune system," said Dr. Amit Patel, Board Member of the Company and Co-Inventor of the Patent Application. "ImmCelz represents a fundamental advancement in regenerative medicine in that instead of administering stem cells in the body to induce immune modulation, we actually optimize the immune modulation in the laboratory before injecting immune cells into the patient."

Being at the forefront in identifying novel regenerative treatment options, the Company possesses numerous issued patents in the area of cellular therapy, including patent no. 10,842,815 covering use of T regulatory cells for spinal disc regeneration, patent no. 9,598,673 covering stem cell therapy for disc regeneration, patent no. 10,792,310 covering regeneration of ovaries using endothelial progenitor cells and mesenchymal stem cells, patent no. 8,372,797 covering use of stem cells for erectile dysfunction, and patent no. 7,569,385 licensed from the University of California covering a novel stem cell type.

"Liver failure represents a significant unmet medical need and I am extremely excited that ImmCelz has the potential to help the numerous patients on the liver transplant waiting list who currently have no other option.

With growing validation and acceptance of such technologies, the company intends to continue to broaden its intellectual property portfolio by compiling research data and filing patents, in order to record early filing dates and increase the likelihood of our receiving patent issue.

We continue to welcome opportunities with collaborators and Key Opinion Leaders as we are dedicated to accelerating the further development of our technology."

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in stem cell technology in the fields of urology, neurology and orthopedics and trades on the OTC under the ticker symbol CELZ. For further information about the company, please visitwww.creativemedicaltechnology.com.

Forward Looking Statements

OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website atwww.sec.gov.

Creativemedicaltechnology.com http://www.StemSpine.com http://www.Caverstem.com http://www.Femcelz.com

1Creative Medical Technology Holdings Identifies Mechanism of Action of ImmCelz Stroke Regenerative Activity (prnewswire.com) 2Creative Medical Technology Holdings Reports Positive Preclinical Data on ImmCelz Immunotherapy Product in Rheumatoid Arthritis Model | BioSpace 3Human endometrial regenerative cells alleviate carbon tetrachloride-induced acute liver injury in mice | Journal of Translational Medicine | Full Text (biomedcentral.com)

SOURCE Creative Medical Technology Holdings, Inc.

http://creativemedicaltechnology.com

Here is the original post:
Creative Medical Technology Holdings Announces Reversion of Liver Failure Using ImmCelz Personalized Cellular Immunotherapy in Preclinical Model -...

Impacts of COVID 19 on Stem Cell Therapy Market 2020 Size, Demand, Opportunities & Forecast To 2026 – Factory Gate

The newly added research report illustrating details on global Stem Cell Therapy market delivers key insights on specific market elements such as competition intensity, regional growth opportunities, vendor profiles and requisite understanding of most potential growth triggers and vendor activities that harbinger growth in global Stem Cell Therapy market. Crucial details on SWOT analysis, PESTEL analysis and Porters Five Forces analytical reviews have been professed with great detail in the report to encourage high investment returns by leading players in global Stem Cell Therapy market. The report carries out a deep analytical study to identify and understand the potential of core factors that stimulate high end growth. The report includes an illustrative overview and serves as an ideal reference point to encourage thoughtful market discretion pertaining to current, historical and future ready business decisions, trends and technologies that have growth steering vigor.

Get PDF Sample Report of Stem Cell Therapy (COVID-19 Version) Market 2020, Click Here @ https://www.adroitmarketresearch.com/contacts/request-sample/691?utm_source=Pallavi

This report gives a complete comprehension of different viewpoints, for example, monetary, creation in the Stem Cell Therapy market. The report contains the current situation of the market by utilizing the effective and exact chronicled information in different market fragments, for example, type and Application Different contextual analyses from different industry specialists are remembered for the report to shape the organizations.

The Stem Cell Therapy market report gives complete data of the development drivers and restrictions that will characterize the business development in the impending years. In addition, it recognizes the open doors existing across the different areas to additional guide business development.

Segmentation Overview The global Stem Cell Therapy market has been examined with ample detailing to disclose vital market specific developments across segment categories. Segment classification of the market structure has been encouraged by our seasoned in-house research experts to allow readers comprehend the versatility of the market in terms of product and service variation. Additional details on regional expanse and geography-based vendor investments are also discussed extensively based on which global Stem Cell Therapy market is splintered into type, application and end-user.

Browse the complete report Along with TOC @ https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market?utm_source=Pallavi

Stem Cell Therapy Market Segmentation Type Analysis of Stem Cell Therapy Market:

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCs Bone Marrow-Derived Mesenchymal SCs Embryonic SCs Other Sources

Applications Analysis of Stem Cell Therapy Market:

Based on therapeutic application, the market has been segmented into,

Musculoskeletal Disorders Wounds & Injuries Cardiovascular Diseases Gastrointestinal Diseases Immune System Diseases Other Applications

COVID-19 Impact on Stem Cell Therapy Market: The outbreak of COVID-19 has brought along a global recession, which has impacted several industries. Along with this impact COVID Pandemic has also generated few new business opportunities for Stem Cell Therapy Market. Overall competitive landscape and market dynamics of Stem Cell Therapy has been disrupted due to this pandemic. All these disruptions and impacts has been analysed quantifiably in this report, which is backed by market trends, events and revenue shift analysis. COVID impact analysis also covers strategic adjustments for Tier 1, 2 and 3 players of Stem Cell Therapy Market.

Table of Contents Includes Major Pointes as follows: 1. Stem Cell Therapy Market Overview 2. Global Stem Cell Therapy Market Competition by Manufacturers 3. Global Stem Cell Therapy Capacity, Production, Revenue (Value) by Region (2014-2019) 4. Global Stem Cell Therapy Supply (Production), Consumption, Export, Import by Region (2014-2019) 5. Global Stem Cell Therapy Production, Revenue (Value), Price Trend by Type 6. Global Stem Cell Therapy Market Analysis by Application 7. Global Stem Cell Therapy Manufacturers Profiles/Analysis 8. Stem Cell Therapy Manufacturing Cost Analysis 9. Industrial Chain, Sourcing Strategy and Downstream Buyers 10. Marketing Strategy Analysis, Distributors/Traders 11. Market Effect Factors Analysis 12. Global Stem Cell Therapy Market Forecast (2019-2026) 13. Research Findings and Conclusion 14. Appendix

If you have any questions on this report, please reach out to us @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691?utm_source=Pallavi

About Us :

Contact Us :

Ryan Johnson Account Manager Global 3131 McKinney Ave Ste 600, Dallas, TX 75204, U.S.A Phone No.: USA: +1 972-362 -8199 / +91 9665341414

Read the original here:
Impacts of COVID 19 on Stem Cell Therapy Market 2020 Size, Demand, Opportunities & Forecast To 2026 - Factory Gate

Efficacy and safety of mesenchymal stem cells for the treatment of patients infected with COVID-19: a systematic review and meta-analysis protocol -…

This article was originally published here

BMJ Open. 2020 Dec 18;10(12):e042085. doi: 10.1136/bmjopen-2020-042085.

ABSTRACT

INTRODUCTION: To date, no specific antivirus drugs or vaccines have been available to prevent or treat the COVID-19 pandemic. Mesenchymal stem cell (MSC) therapy may be a promising therapeutic approach that reduces the high mortality in critical cases. This protocol is proposed for a systematic review and meta-analysis that aims to evaluate the efficacy and safety of MSC therapy on patients with COVID-19.

METHODS AND ANALYSIS: Ten databases including PubMed, EMBASE, Cochrane Library, CINAHL, Web of Science, Chinese National Knowledge Infrastructure (CNKI), Chinese Scientific Journals Database (VIP), Wanfang database, China Biomedical Literature Database (CBM) and Chinese Biomedical Literature Service System (SinoMed) will be searched from inception to 1 December 2020. All published randomised controlled trials, clinical controlled trials and case series that meet the prespecified eligibility criteria will be included. The primary outcomes include mortality, incidence and severity of adverse events, respiratory improvement, days from ventilator, duration of fever, progression rate from mild or moderate to severe, improvement of such serious symptoms as difficulty breathing or shortness of breath, chest pain or pressure, and loss of speech or movement, biomarkers of laboratory examination and changes in CT. The secondary outcomes include dexamethasone doses and quality of life. Two reviewers will independently perform study selection, data extraction and assessment of bias risk. Data synthesis will be conducted using RevMan software (V.5.3.5). If necessary, subgroup and sensitivity analysis will be performed. Grading of Recommendations Assessment, Development and Evaluation system will be used to assess the strength of evidence.

ETHICS AND DISSEMINATION: Ethical approval is not necessary since no individual patient or privacy data have been collected. The results of this review will be disseminated in a peer-reviewed journal or an academic conference presentation.

PROSPERO REGISTRATION NUMBER: CRD42020190079.

PMID:33371042 | DOI:10.1136/bmjopen-2020-042085

Original post:
Efficacy and safety of mesenchymal stem cells for the treatment of patients infected with COVID-19: a systematic review and meta-analysis protocol -...